{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:01:18Z","timestamp":1793642478827,"version":"4.5.1"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Program of Shaanxi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Definity significantly enhances the diagnostic accuracy of echocardiography but raises ongoing safety concerns. This study aimed to explore potential adverse events (AEs) associated with Definity in real-world settings by analyzing data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively extracted AE reports from the FAERS database between 2004 and the first quarter of 2024. Disproportionality analyses using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) were conducted to identify signals potentially associated with Definity. Univariate and multivariate logistic regression analyses were performed as sensitivity analyses to assess potential risk factors for Definity-related AEs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 4460 reports with Definity as the \u201cprimary suspected\u201d drug were included. We identified 104 statistically significant signals at PT level, including common AEs such as back pain and muscle spasms, as well as exploratory signals not listed on the drug label, such as eye movement disorder and renal pain. It is noteworthy that 21 signals did not retain significance following Bonferroni correction. These AEs spanned 25 System Organ Classes (SOCs). In reports with available time-to-onset data, most events occurred within 30 days of administration, while some were reported at longer intervals. Moreover, logistic regression analysis indicated that both gender and body weight were independent risk factors associated with Definity-related AE.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study provides exploratory insights into potential AEs associated with Definity based on real-world pharmacovigilance data. While most signals are consistent with known safety profiles, several emerging signals warrant further investigation and clinical awareness. These findings may contribute to ongoing risk management and pharmacovigilance efforts.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0331444","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T17:38:06Z","timestamp":1756489086000},"page":"e0331444","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Definity"],"prefix":"10.1371","volume":"20","author":[{"given":"Wanting","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-9342","authenticated-orcid":true,"given":"Menghao","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"10","key":"pone.0331444.ref001","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jcmg.2018.06.020","article-title":"3-Dimensional Echocardiography: Moving From Pretty Pictures Toward Patient Outcomes","volume":"12","author":"P Thavendiranathan","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"pone.0331444.ref002","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/fca-2020-0049","article-title":"Review of ultrasound contrast agents in current clinical practice with special focus on DEFINITY\u00ae in cardiac imaging","volume":"17","author":"M Salih","year":"2021","journal-title":"Future Cardiol"},{"issue":"1","key":"pone.0331444.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40360-023-00729-z","article-title":"Pharmacokinetics and pharmacodynamics of perfluoropropane after intra-venous bolus injection of perflutren lipid microsphere injection (DEFINITY\u00ae) in healthy Chinese volunteers","volume":"25","author":"P Li","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"pone.0331444.ref004","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005459","article-title":"Safety With Echocardiographic Contrast Agents","volume":"10","author":"PR Muskula","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"pone.0331444.ref005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update","volume":"31","author":"TR Porter","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"issue":"11","key":"pone.0331444.ref006","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.echo.2008.09.009","article-title":"American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography","volume":"21","author":"SL Mulvagh","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"pone.0331444.ref007","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ultrasmedbio.2019.12.008","article-title":"Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements","volume":"46","author":"P Frinking","year":"2020","journal-title":"Ultrasound Med Biol"},{"issue":"12","key":"pone.0331444.ref008","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.echo.2020.07.015","article-title":"Identification of Need for Ultrasound Enhancing Agent Study (the IN-USE Study)","volume":"33","author":"AM Fraiche","year":"2020","journal-title":"J Am Soc Echocardiogr"},{"issue":"25","key":"pone.0331444.ref009","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.jacc.2007.11.006","article-title":"Thinking outside the \u201cbox\u201d-the ultrasound contrast controversy","volume":"50","author":"ML Main","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0331444.ref010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcmg.2013.11.003","article-title":"Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts","volume":"7","author":"A Kalra","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"pone.0331444.ref011","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.echo.2008.07.019","article-title":"The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses","volume":"21","author":"K Wei","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"pone.0331444.ref012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"J Szebeni","year":"2005","journal-title":"Toxicology"},{"issue":"5","key":"pone.0331444.ref013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.echo.2022.02.006","article-title":"Hypersensitivity Cross-Reactivity for Ultrasound-Enhancing Agents and COVID-19 Vaccines","volume":"35","author":"AK Desai","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"pone.0331444.ref014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.echo.2021.05.002","article-title":"Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol","volume":"34","author":"JR Lindner","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"pone.0331444.ref015","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/ehjci\/jeab120","article-title":"Ultrasound contrast agent hypersensitivity in patients allergic to polyethylene glycol: position statement by the European Association of Cardiovascular Imaging","volume":"22","author":"R Senior","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"pone.0331444.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.04.037","article-title":"Recurrent Lethal Allergic Coronary Vasospasm","volume":"133","author":"M Elzeneini","year":"2020","journal-title":"Am J Med"},{"issue":"2","key":"pone.0331444.ref017","article-title":"Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast","volume":"5","author":"A D\u2019Amico","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"pone.0331444.ref018","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"C Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"pone.0331444.ref019","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"L Meng","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"6","key":"pone.0331444.ref020","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database","volume":"52","author":"X Zhang","year":"2024","journal-title":"Infection"},{"key":"pone.0331444.ref021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System","volume":"14","author":"Y Shu","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"4","key":"pone.0331444.ref022","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0331444.ref023","doi-asserted-by":"crossref","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Z Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0331444.ref024","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"pone.0331444.ref025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"EG Brown","year":"2004","journal-title":"Drug Saf"},{"issue":"1","key":"pone.0331444.ref026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0331444.ref027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","article-title":"Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports","volume":"40","author":"ZA Trippe","year":"2017","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0331444.ref028","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database","volume":"52","author":"X Zhang","year":"2024","journal-title":"Infection"},{"issue":"4","key":"pone.0331444.ref029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"N Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0331444.ref030","doi-asserted-by":"crossref","first-page":"1369384","DOI":"10.3389\/fphar.2024.1369384","article-title":"Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database","volume":"15","author":"S Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0331444.ref031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database","volume":"346","author":"Y Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"pone.0331444.ref032","doi-asserted-by":"crossref","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","article-title":"Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)","volume":"15","author":"M-T Wen","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0331444.ref033","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.2147\/IJN.S490400","article-title":"Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database","volume":"19","author":"Y-C Zhao","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"pone.0331444.ref034","article-title":"A disproportionality analysis of thromboembolic and cardiovascular adverse event signal strength across various JAK-inhibitors based on the FAERS database","author":"X Zheng","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0331444.ref035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","article-title":"Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study","volume":"43","author":"ST de Vries","year":"2020","journal-title":"Drug Saf"},{"issue":"11","key":"pone.0331444.ref036","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/AAC.00644-10","article-title":"Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance","volume":"54","author":"KS Long","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0331444.ref037","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40264-015-0332-6","article-title":"Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database","volume":"38","author":"M Hauben","year":"2015","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0331444.ref038","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/echo.14344","article-title":"Safety profile of ultrasound enhancing agents in echocardiography","volume":"36","author":"S Kumar","year":"2019","journal-title":"Echocardiography"},{"issue":"12","key":"pone.0331444.ref039","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.7150\/thno.70372","article-title":"Theranostics in the vasculature: bioeffects of ultrasound and microbubbles to induce vascular shutdown","volume":"13","author":"F Padilla","year":"2023","journal-title":"Theranostics"},{"issue":"7","key":"pone.0331444.ref040","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ultrasmedbio.2006.03.013","article-title":"The potential for enhancement of mouse melanoma metastasis by diagnostic and high-amplitude ultrasound","volume":"32","author":"DL Miller","year":"2006","journal-title":"Ultrasound Med Biol"},{"issue":"1","key":"pone.0331444.ref041","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2176\/nmc.53.34","article-title":"Repeated injection of contrast medium inducing dysfunction of the blood-brain barrier: case report","volume":"53","author":"T Iwata","year":"2013","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"12","key":"pone.0331444.ref042","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.echo.2013.08.004","article-title":"Renal retention of lipid microbubbles: a potential mechanism for flank discomfort during ultrasound contrast administration","volume":"26","author":"YN Liu","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"issue":"7500","key":"pone.0331444.ref043","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","article-title":"Policy: NIH to balance sex in cell and animal studies","volume":"509","author":"JA Clayton","year":"2014","journal-title":"Nature"},{"issue":"2","key":"pone.0331444.ref044","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1667\/0033-7587(2003)159[0190:ODDAAM]2.0.CO;2","article-title":"Oxygen depletion during and after mTHPC-mediated photodynamic therapy in RIF1 and H-MESO1 tumors","volume":"159","author":"H Schouwink","year":"2003","journal-title":"Radiat Res"},{"key":"pone.0331444.ref045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.12688\/hrbopenres.13355.1","article-title":"Are behaviour change techniques and intervention features associated with effectiveness of digital cardiac rehabilitation programmes? A systematic review protocol","volume":"4","author":"E Kenny","year":"2021","journal-title":"HRB Open Res"},{"issue":"10","key":"pone.0331444.ref046","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"HC Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"37","key":"pone.0331444.ref047","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1039\/c2ob26295a","article-title":"Highly selective synthesis of tetra-substituted furans and cyclopropenes: copper(I)-catalyzed formal cycloadditions of internal aryl alkynes and diazoacetates","volume":"10","author":"AK Swenson","year":"2012","journal-title":"Org Biomol Chem"},{"issue":"1","key":"pone.0331444.ref048","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"UM Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"10","key":"pone.0331444.ref049","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/17425255.2022.2132931","article-title":"Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes","volume":"18","author":"T Zhang","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"pone.0331444.ref050","doi-asserted-by":"crossref","first-page":"23562","DOI":"10.1038\/s41598-024-72439-3","article-title":"Overgeneralization of autonomic defensive reactions in obesity","volume":"14","author":"E Manassero","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0331444.ref051","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"KB Hoffman","year":"2014","journal-title":"Drug Saf"},{"issue":"3","key":"pone.0331444.ref052","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength","volume":"56","author":"R Neha","year":"2021","journal-title":"Hosp Pharm"},{"issue":"1","key":"pone.0331444.ref053","article-title":"Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events","volume":"34","author":"W Bai","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T17:38:14Z","timestamp":1756489094000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331444"}},"subtitle":[],"editor":[{"given":"Jingjing","family":"Qian,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331444","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}